Addex Therapeutics Ltd (ADXN)
NASDAQ: ADXN · Real-Time Price · USD
9.20
+0.38 (4.37%)
Jun 27, 2025, 4:00 PM - Market closed
Addex Therapeutics Revenue
Addex Therapeutics had revenue of 71.06K CHF in the quarter ending March 31, 2025, a decrease of -69.75%. This brings the company's revenue in the last twelve months to 246.19K, down -81.76% year-over-year. In the year 2024, Addex Therapeutics had annual revenue of 410.04K, down -74.64%.
Revenue (ttm)
246.19K CHF
Revenue Growth
-81.76%
P/S Ratio
26.11
Revenue / Employee
123,094 CHF
Employees
2
Market Cap
7.27M USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 410.04K | -1.21M | -74.64% |
Dec 31, 2023 | 1.62M | 172.23K | 11.92% |
Dec 31, 2022 | 1.44M | -1.71M | -54.18% |
Dec 31, 2021 | 3.15M | -725.84K | -18.71% |
Dec 31, 2020 | 3.88M | 1.05M | 36.89% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ADXN News
- 2 days ago - Addex Shareholders Approve All Resolutions at Annual General Meeting - GlobeNewsWire
- 8 days ago - Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 9 days ago - Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025 - GlobeNewsWire
- 21 days ago - Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical Models - GlobeNewsWire
- 24 days ago - Addex Convenes Annual General Meeting 2025 - GlobeNewsWire
- 6 weeks ago - Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies - GlobeNewsWire
- 2 months ago - Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery - GlobeNewsWire
- 2 months ago - Addex Therapeutics Ltd (ADXN) Q4 2024 Earnings Call Transcript - Seeking Alpha